MYGN vs SLB · rev $837.6M vs P/E 12, rev $8.97B
Myriad Genetics Inc (MYGN) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
MYGN currently screens at market cap $413.7M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the MYGN and SLB stock pages for the full models.
Not investment advice.